Stryker (NYSE: SYK) reported Q4 EPS of $2.71, $0.01 worse than the analyst estimate of $2.72. Revenue for the quarter came in at $4.7 million versus the consensus estimate of $4.65 million.

GUIDANCE:

Stryker sees FY2022 EPS of $9.60-$10.00, versus the consensus of $10.14.

• We continue to monitor and evaluate the impact the global response to the COVID-19 pandemic has had, and will continue to have, on our operations and financial results. As we assess the impact of the pandemic on our operations and the external environment we believe the short-term outlook remains volatile. We expect 2022 organic net sales growth to be in the range of 6% to 8% and expect adjusted net earnings per diluted share(2) to be in the range of $9.60 to $10.00. Consistent with the pricing environment experienced in previous years, we expect continued unfavorable price reductions of approximately 1% in 2022. If foreign exchange rates hold near their current levels, we anticipate sales and EPS will be modestly unfavorably impacted as compared to 2021.

For earnings history and earnings-related data on Stryker (SYK) click here.